BiotechTube
Home/ORIC Pharmaceuticals/Kevin Brodbeck, PhD
KB

Kevin Brodbeck, PhD

Chief Technical Officer

ORIC Pharmaceuticals

Therapeutic Areas

Oncology

ORIC Pharmaceuticals Pipeline

DrugIndicationPhase
Enozertinib (ORIC-114)NSCLC (EGFR exon 20 & PACC mutations)Phase 1b/2
Rinzimetostat (ORIC-944)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 1b/2
ORIC-101Multiple Solid TumorsPhase 1b
ORIC-533Multiple MyelomaPhase 1b

Leadership Team at ORIC Pharmaceuticals

JC
Jacob Chacko, MD
President, Chief Executive Officer and Board Member
View full ORIC Pharmaceuticals profile